Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Hematol.

Sec. Blood Cancer

Volume 4 - 2025 | doi: 10.3389/frhem.2025.1527938

Co-occurrence of AIDS and Acute Promyelocytic Leukemia: A Case Report and Review of the Literature

Provisionally accepted
  • 1Hangzhou City University, Hangzhou, China
  • 2Yuyao People's Hospital, Yuyao, Zhejiang, China

The final, formatted version of the article will be published soon.

Acute promyelocytic leukemia (APL) is a rare and aggressive subtype of acute myelogenous leukemia (AML), characterized by the PML-RARA fusion gene. When APL presents concurrently with acquired immunodeficiency syndrome (AIDS), it creates unique challenges in diagnosis and treatment due to the immunocompromised state of the patient. This case report describes a 46-year-old male patient with long-standing AIDS who developed APL. Initial treatment involved all-trans retinoic acid (ATRA) monotherapy due to the patient's severe lung infection and liver dysfunction, followed by the addition of arsenic trioxide (ATO) once infection and liver function improved. The patient achieved complete remission (CR) after combined ATRA and ATO therapy, with successful molecular remission of the PML-RARA fusion gene. We discuss the complexity of managing APL in the context of HIV infection, including the challenges posed by infections, liver dysfunction, and the impact of chemotherapy on antiretroviral therapy (ART). This case highlights the need for immediate initiation of ATRA in APL patients, even before genetic confirmation, and the potential therapeutic role of ATO in both leukemia treatment and HIV reservoir management.Further studies are needed to optimize treatment protocols for patients with concurrent AIDS and APL, focusing on personalized approaches to maximize efficacy while minimizing complications.

Keywords: Acute promyelocytic leukemia (APL), Acquired immunodeficiency syndrome (AIDS), All-trans retinoic acid (ATRA), Arsenic trioxide (ATO), PML-RARA fusion gene

Received: 14 Nov 2024; Accepted: 26 Jun 2025.

Copyright: © 2025 Duan, Ai, Shentu, Xu and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Shiwei Duan, Hangzhou City University, Hangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.